Related Experiment Video
Updated: Jan 25, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Adjuvant therapy of gastrointestinal stromal tumors
Vadim P Koshenkov1, Steven E Rodgers
1Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Purpose Of Review:
The treatment of gastrointestinal stromal tumors (GISTs) with tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, has produced improved outcomes and survival. However, patients with high-risk tumors still have unacceptably high rates of recurrence and disease progression. In the current review, we examine the various strategies for optimizing the treatment of GISTs.
Recent Findings:
Extended duration of treatment (36 months) with adjuvant imatinib resulted in improved recurrence-free survival and overall survival, whereas discontinuation of the TKI led to relapse of disease in most high-risk patients. High-dose therapy of imatinib was beneficial for patients with KIT exon 9 mutations. Patients with KIT exon 11 mutations experienced the most improvement in outcomes from adjuvant imatinib.
Summary:
The extended duration of TKI treatment, dose optimization, mutation status, and the effects of TKI discontinuation have recently been examined in more detail. As our understanding of TKI therapy grows, an individualized approach to each patient should lead to better outcomes.
Insights
Optimizing tyrosine kinase inhibitor (TKI) treatment for gastrointestinal stromal tumors (GISTs) is crucial. Extended TKI duration and dose adjustments improve outcomes, especially for high-risk patients with specific mutations.
Area of Science:
- Oncology
- Gastrointestinal Oncology
- Molecular Targeted Therapy
Background:
- Gastrointestinal stromal tumors (GISTs) are treated with tyrosine kinase inhibitors (TKIs), improving patient outcomes.
- High-risk GIST patients still face significant recurrence and progression rates despite TKI therapy.
Purpose of the Study:
- To review strategies for optimizing TKI treatment in GIST.
- To explore factors influencing treatment efficacy and recurrence.
Main Methods:
- Review of current literature on TKI therapy for GIST.
- Analysis of treatment duration, dosage, mutation status, and discontinuation effects.
Main Results:
- Extended adjuvant imatinib therapy (36 months) improved recurrence-free and overall survival.
- High-dose imatinib benefited patients with KIT exon 9 mutations.
- Patients with KIT exon 11 mutations showed the greatest improvement with adjuvant imatinib.
Conclusions:
- TKI treatment duration, dose optimization, and mutation status are key factors in GIST management.
- Discontinuation of TKIs can lead to disease relapse in high-risk patients.
- An individualized approach to TKI therapy is essential for better GIST patient outcomes.
Related Concept Videos
01:26Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:
01:20Histology of the Gastrointestinal (GI) Tract
The mucosa is sometimes called a mucous membrane due to its mucus-secreting features. This membrane is composed of epithelium, which directly interacts with ingested substances, and the lamina propria, a layer...
01:20Gastrointestinal Motility Disorders
01:22Physiology of the Gastrointestinal System I: Ingestion and Propulsion
01:22Physiology of the Gastrointestinal System II: Digestion and Absorption
Digestion begins in the mouth, where food undergoes mechanical breakdown by chewing and combines with saliva. Salivary amylase, an enzyme in saliva, starts the breakdown of starches into maltose. The food then travels down the esophagus to the stomach.
In the stomach, a...
01:26Physiology of the Gastrointestinal System III: Elimination